Drugs / Multipeptide Vaccine AML-VAC-XS15
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06252584 | May 2024 → May 2026 overdue | acute myeloid leukemia | University Hospital Tuebingen | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multipeptide Vaccine AML-VAC-XS15 | “Multipeptide Vaccine AML-VAC-XS15” NCT06252584 ↗ |
| Modality | Vaccine | “Peptide vaccine: Multi-peptide vaccine cocktail” NCT06252584 ↗ |
| Route | Subcutaneous | “administered subcutaneously (s.c.)” NCT06252584 ↗ |